# ALGONQUIN (NCT03715478)

> Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex

No report yet. It can be ordered.

- Drugs tested: belantamab mafodotin plus pomalidomide plus dexamethasone
- Indication: relapsed and/or refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03715478
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Canadian Myeloma Research Group
- Conditions: Relapsed and/or Refractory Multiple Myeloma
- Interventions: GSK2857916 with Pomalidomide and Dexamethasone
- Enrollment: 120
- Primary outcome: Recommended Phase 2 Dose (RP2D)
- Primary outcome: Overall Response Rate (ORR)

## Some of the questions raised in the 21 indexed sources

_Automated from all 21 indexed sources (Sep 2022 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether less frequent belantamab dosing keeps response depth while reducing ocular events
- Whether single-arm results reflect patient selection rather than benefit over a historical control
- Whether prior anti-CD38 refractoriness or triple-class refractory status changes benefit from belantamab-pomalidomide-dexamethasone
- Whether γδ T-cell expansion and T-cell receptor repertoire can identify who responds to belantamab

## Indexed commentary on ALGONQUIN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 6 YouTube videos
- 4 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=algonquin-nct03715478

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03715478", "email": "<work email>"}; the inbox owner confirms by the emailed link.
